Colorectum

Colorectal cancer (CRC) remains the third most commonly diagnosed malignancy and the second leading cause of cancer-related death globally. The majority arise from adenomatous polyps via the adenoma-carcinoma sequence, providing a unique window for prevention through screening. This review covers the epidemiology, molecular pathogenesis, clinical presentation, staging, multidisciplinary management, and surveillance strategies for colorectal tumors, incorporating current NCCN, ESMO, and ASCO guidelines.

1. Epidemiology & Risk Stratification

• Incidence: ~1.9 million new cases annually worldwide (GLOBOCAN 2020). Rising incidence in adults < 50 years (Early-Onset CRC) necessitates updated screening guidelines (USPSTF/ACS now recommend initiation at age 45 for average-risk individuals).
• Risk Categories:
  • Average Risk: Age ≥ 45, no personal/family history.
  • Increased Risk: Personal history of adenomas, CRC, or IBD (Ulcerative Colitis > 8 yrs / Crohn’s colitis); Family history of CRC or advanced adenoma in 1st-degree relative < 60 yrs (or 2 FDRs at any age).
  • High Risk (Genetic Syndromes): Lynch Syndrome (LS/HNPCC), Familial Adenomatous Polyposis (FAP), MUTYH-Associated Polyposis (MAP), Hamartomatous Polyposis Syndromes (Peutz-Jeghers, Juvenile Polyposis).

2. Molecular Pathogenesis: The “Vogelstein” Sequence & Beyond

CRC is a heterogeneous disease defined by distinct molecular pathways driving the transition from normal epithelium $\to$ adenoma $\to$ carcinoma.

Critical Biomarkers for Therapy Selection (Mandatory at Diagnosis):

1. MMR/MSI Status: IHC (MLH1, PMS2, MSH2, MSH6) or PCR/NGS. Reflex MLH1 methylation/BRAF V600E if MLH1/PMS2 loss to rule out Lynch.
2. RAS (KRAS/NRAS Exons 2, 3, 4) & BRAF V600E: Predicts anti-EGFR resistance (Cetuximab/Panitumumab).
3. HER2 Amplification: Targetable in RAS/BRAF WT metastatic disease (trastuzumab/pertuzumab/tucatinib).
4. NTRK Fusions / RET Fusions: Rare (<1%), targetable with TRK/RET inhibitors.
5. TMB-H / MSI-H: Pan-tumor indication for Pembrolizumab/Dostarlimab.

3. Histologic Classification (WHO 2019/2022 Updates)

• Adenocarcinoma (NOS): >95%. Graded Low-grade (Well/Mod) vs. High-grade (Poor/Undifferentiated).
• Aggressive Variants (Require specific mention in report):
  • Mucinous Adenocarcinoma: >50% extracellular mucin. Associated with MSI-H, peritoneal spread, KRAS mut, BRAF mut. Poor response to standard chemo.
  • Signet Ring Cell Carcinoma (SRCC): >50% signet ring cells. Worst prognosis, young age, peritoneal carcinomatosis, linitis plastica morphology.
  • Medullary Carcinoma: Syncytial growth, pushing borders, intense TILs. Strongly MSI-H/dMMR. Excellent prognosis if early stage; ICI responsive.
  • Micropapillary Component: High metastatic potential, adverse prognostic factor.
• Precursors:
  • Conventional Adenoma: Tubular, Tubulovillous, Villous. Low/High grade dysplasia.
  • Serrated Lesions: Hyperplastic Polyp (HP – distal, <5mm, no malignant potential), Sessile Serrated Lesion (SSL – proximal, >10mm, dysplasia = high risk), Traditional Serrated Adenoma (TSA).

4. Clinical Presentation & Diagnostic Workup

Diagnostic Algorithm:

1. Colonoscopy (Gold Standard): Full visualization to cecum/terminal ileum. Mandatory: Photo-documentation, tattooing (if lesion not readily reachable by scope), biopsy, polyp resection (EMR/ESD).
2. CT Chest/Abdomen/Pelvis (CAP) with Contrast: Standard staging for clinical T3/T4 or N+ disease; evaluates metastatic disease (liver, lung, peritoneum, nodes).
3. MRI Pelvis (Rectal Cancer ONLY): Mandatory for primary staging (mrT, mrN, CRM status, EMVI, mesorectal fascia involvement). Dictates neoadjuvant strategy.
4. Endorectal Ultrasound (ERUS): Alternative for early rectal cancer (T1/T2) if MRI contraindicated; assesses sphincter involvement.
5. PET-CT: Not routine for primary staging. Indicated for equivocal metastatic lesions on CT or recurrent disease workup.
6. Serum CEA: Baseline pre-op (prognostic if elevated > 5 ng/mL); monitoring response/recurrence. Not a screening tool.

5. Staging: TNM 8th Edition (AJCC/UICC) – Clinical vs. Pathologic

• cTNM: Imaging/Endoscopy (Guides neoadjuvant therapy).
• pTNM: Surgical Specimen (Gold standard prognosis).
• y(p)TNM: Post-neoadjuvant therapy.
• Key Prognostic Modifiers:
  • Tumor Deposits (TDs): Discrete nodules in pericolorectal fat without nodal tissue. Counted as pN1c (if no positive nodes) or added to N-count. Poor prognosis.
  • Circumferential Resection Margin (CRM): < 1 mm = Positive (R1). Critical in rectal cancer MRI reporting.
  • Extramural Venous Invasion (EMVI): MR-EMVI or histologic. Adverse prognosis.
  • Tumor Regression Grade (TRG): Post-neoadjuvant (Mandard, Dworak, or CAP systems). TRG 0/1 (Complete/Near Complete Response) $\to$ Organ Preservation candidate.

6. Multidisciplinary Management (MDT Mandatory)

A. Colon Cancer

B. Rectal Cancer (Distinct from Colon – Distance from Anal Verge < 15 cm / below peritoneal reflection)

Risk Stratification by MRI (mrT/mrN/CRM/EMVI):

• Early (cT1-2, N0, CRM-): Local Excision (TEM/TAMIS) if favorable histology (G1/2, no LVI, < 3cm, < 30% circumference). Radical Surgery (TME) if adverse features or positive margin post-local excision.
• Locally Advanced (LARC): cT3-4 and/or N+
  • Historical Standard: Neoadjuvant Chemoradiation (nCRT: 50.4 Gy + 5-FU/Cape) $\to$ Surgery (TME) $\to$ Adjuvant Chemo.
  • Current Paradigm Shift (TNT – Total Neoadjuvant Therapy):
    • PROSPECT / RAPIDO / OPRA Trials: Neoadjuvant Chemo (FOLFOX/CAPOX x 4-6 cycles) $\to$ Short Course RT (5×5 Gy) OR Long Course CRT $\to$ Surgery.
    • Benefit: Higher pathologic Complete Response (pCR), higher sphincter preservation, less distant failure, avoids permanent stoma in select “Watch & Wait” patients.
  • Short Course RT (5×5 Gy) $\to$ Immediate Surgery: Option for low-risk LARC (clear CRM on MRI) or frail patients (Stockholm III).
• Organ Preservation (“Watch & Wait”):
  • Strict Criteria: Clinical Complete Response (cCR) on MRI (mrTRG 1-2), Endoscopy (white scar/normal mucosa), DRE, CEA normalization.
  • Mandatory: Rigorous Surveillance Protocol (q3-4mo x 2yrs: MRI, Endoscopy, DRE, CEA). Local Regrowth $\to$ Salvage TME.
• Metastatic Rectal Cancer: Systemic therapy primary. Local RT only for symptomatic primary (obstruction/bleeding/pain).

7. Surgical Principles

• Colon: Complete Mesocolic Excision (CME) with Central Vascular Ligation (CVL). High ligation of vascular pedicles (Ileocolic, Right Colic, Middle Colic, IMA). Minimum 12 Lymph Nodes for accurate staging.
• Rectum: Total Mesorectal Excision (TME) – Sharp dissection in the “Holy Plane” (areolar plane between mesorectal fascia and parietal fascia).
  • Sphincter Preservation (LAR/ILA): Possible if distal clearance $\ge$ 1-2 cm (stapler), adequate sphincter function, no levator invasion.
  • Abdominoperineal Resection (APR): Extralevator (ELAPE/cylindrical) for low tumors $\to$ Lower CRM+ rates.
• Minimally Invasive (Lap/Robotic): Standard of care (COLOR II, ACOSOG Z6051, ROLARR). Robotic advantage in narrow pelvis (rectal), obese patients.

8. Post-Treatment Surveillance (ASCO/NCCN/ESMO Consensus)

Goal: Detect curable recurrence (local, liver, lung) & metachronous neoplasia.

Duration: 5 Years (Recurrence risk drops <1% after 5 yrs for Stage I-III). Lifelong colonoscopy for metachronous polyps.

9. Special Clinical Scenarios

1. Malignant Polyps (T1 / pT1):
   • Favorable (Low Risk): Well/Mod differentiated, No LVI/PNI, Margin $\ge$ 1mm, No tumor budding (Budding Low). $\to$ Surveillance only (Colonoscopy 6-12 mo).
   • Unfavorable (High Risk): Any Poor diff, LVI+, PNI+, Margin <1mm, Budding High, Sm3 Deep Submucosal Invasion. $\to$ Formal Oncologic Resection + LN Dissection.
   • Serrated morphology (SSL w/ dysplasia/carcinoma): Manage per adenocarcinoma risk features; ensure complete baseline colonoscopy.
2. Obstructing Colon Cancer:
   • Stable: Self-Expanding Metal Stent (SEMS) as Bridge to Surgery (BTS) $\to$ Elective Laparoscopic Resection (Primary Anastomosis). Avoids stent-perforation risk if chemo planned (wait 2-3 wks post-stent).
   • Unstable/Perforation: Emergent Resection (Hartmann’s or Subtotal Colectomy $\pm$ Stoma).
3. Lynch Syndrome (LS) Management:
   • Tumor Testing (IHC/MSI) $\to$ Germline Genetic Testing.
   • Surveillance: Colonoscopy q 1-2 years starting age 20-25 (or 2-5 yrs < earliest Dx in family).
   • Surgery: Subtotal Colectomy + IRA (Ileorectal Anastomosis) preferred over Segmental for CRC (lower metachronous risk). Aspirin 600mg/day (CAPP2) for chemoprevention.
4. Inflammatory Bowel Disease (IBD)-Associated Neoplasia:
   • Surveillance Colonoscopy 8-10 yrs post-pancolitis Dx (15 yrs left-sided).
   • DALM (Dysplasia-Associated Lesion or Mass) / Visible Dysplasia: Endoscopic Resection (R0) $\to$ Surveillance. Invisible High-Grade Dysplasia / Multifocal LGD / Failed ER: Proctocolectomy.

10. Key Takeaways for the Clinician

1. Screening Saves Lives: Initiate at 45 (Average Risk). Colonoscopy remains the only “preventative” test (polypectomy).
2. Molecular Profiling is Standard of Care: MMR/MSI, RAS, BRAF, HER2 must be resulted before 1st line metastatic therapy discussion.
3. Rectal Cancer = Colon Cancer: MRI Staging + MDT $\to$ TNT (Chemo $\pm$ RT) $\to$ Organ Preservation Strategy is the modern paradigm.
4. Stage II Adjuvant Nuance: dMMR/MSI-H = No 5-FU. High Risk MSS = Discuss Oxaliplatin benefit vs. toxicity (3 mos CAPOX).
5. Surveillance is Curative-Intent: Structured CEA + Imaging + Endoscopy detects resectable recurrence.
6. Genetics Matter: Universal Tumor MMR Testing $\to$ Identify Lynch Syndrome $\to$ Cascade Testing $\to$ Cancer Prevention in Families.

References (Selected Landmark Guidelines & Trials)

1. NCCN Guidelines: Colon Cancer / Rectal Cancer / Genetic/Familial High-Risk Assessment (V.2.2024+).
2. ESMO Clinical Practice Guidelines: Colon Cancer (Ann Oncol 2023), Rectal Cancer (Ann Oncol 2023).
3. IDEA Collaboration (Grothey et al., NEJM 2018) – 3 vs 6 mos Adjuvant.
4. PROSPECT Trial (Schrag et al., NEJM 2023) – Neoadjuvant FOLFOX $\to$ Selective RT.
5. RAPIDO Trial (Bahadoer et al., Lancet Oncol 2021) – TNT vs Standard.
6. KEYNOTE-177 (André et al., NEJM 2020) – 1st Line Pembro for MSI-H mCRC.
7. BEACON Trial (Kopetz et al., NEJM 2020) – Encorafenib/Cetuximab for BRAF V600E.
8. CAPP2 Trial (Burn et al., Lancet 2020) – Aspirin in Lynch Syndrome.
9. DYNAMIC / CIRCULATE-Japan (Tie et al., NEJM 2022 / Yamada et al., Nature Med 2022) – ctDNA guided adjuvant.
10. WHO Classification of Tumours: Digestive System Tumours (5th Ed, 2019/2022).

Disclaimer: This article is intended for educational purposes for licensed healthcare professionals. It does not substitute for individualized clinical judgment, institutional protocols, or the most current versions of cited guidelines. Dosages and indications require verification against current FDA/EMA labeling and local formularies.